[关于CCL4对瘤微环境中的免疫逃脱的影响的研究进展]
Ran Chen1,2, Xinyue Yang3, Qian Liu1
1Department of Oncology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, China.
Zhongguo fei ai za zhi = Chinese journal of lung cancer
|September 25, 2024
概括
C-C 化学因子连接物4 (CCL4) 是一种促进瘤生长和免疫规避的细胞因子. 了解 CCL4 的理解
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物化学 生化学
背景情况:
- 免疫疗法是癌症的关键治疗方法,但患者的反应有很大差异.
- 生物标志物是预测免疫治疗疗效的必要条件.
- 在瘤中,CCL4 (C-C 化学因配体4) 的调节升高,并影响瘤的微环境.
研究的目的:
- 审查CCL4在瘤免疫微环境 (TME) 中的作用.
- 探索CCL4对免疫逃生机制的影响.
- 为改善癌症免疫疗法提供见解.
主要方法:
- 关于CCL4和癌症免疫学研究的文献综述.
- 对CCL4与其受体CCR5.5的相互作用进行分析.
- 检查CCL4在免疫细胞招募和TME中的功能中的作用.
主要成果:
- 由瘤和免疫细胞分泌的CCL4可以招募单细胞,巨细胞,NK细胞和T细胞.
- CCL4与CCR5结合会破坏TME并促进瘤的发展.
- 异常的CCL4表达与各种恶性瘤有关.
结论:
- CCL4是瘤免疫逃逸的一个重要因素.
- CCL4具有作为免疫疗法疗效的生物标志物的潜力.
- 对CCL4的进一步研究可以指导临床诊断和治疗策略.
关键词:
CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4 CCL4免疫逃脱是为了逃脱免疫.免疫反应的免疫反应.免疫治疗是一种免疫疗法.瘤微环境是一个微环境.更多相关视频
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cytotoxic T Cells-mediated Immune Response
858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


